Established executive with a successful track record and experience in a variety of settings from start-ups to large biotech companies. Member of the Anadys management team whose collective efforts led to the $230M acquisition of the company by Roche. Sourced and closed significant license and collaboration agreements with a majority of the top biopharmaceutical companies; with an aggregate value of potential payments in excess of $1.3 billion and with actualized payments in excess of $500 million. Co-founder Achillion Pharmaceuticals and eFFECTOR Therapeutics.Specialties: Licensing, M&A, Capital Formation